LITERATURE
原始候选快照
v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。
| 论文 | 标识 | 日期 | 入排置信度 | 入排依据 | KM 状态 |
|---|---|---|---|---|---|
| Transanal total mesorectal excision versus laparoscopic total mesorectal excision for mid and low rectal cancer (COLOR III): short-term outcomes of an international, multicentre, phase 3, randomised, controlled, non-inferiority trial.Lancet Gastroenterol HepatolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41887239无 PMCID | 2026-May | 0.93 | 干预为非药物单独策略,未满足药物干预要求。 | 无 KM 图 |
| Polymyxin B haemoadsorption in endotoxic septic shock (Tigris): a multicentre, open-label, Bayesian, randomised, controlled, phase 3 trial.Lancet Respir MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41887242无 PMCID | 2026-May | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Minimal important differences of EORTC QLQ-C30 and QLQ-BR23 for metastatic breast cancer patients in a Japanese population: results from the RESQ trial.Breast CancerPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41910921无 PMCID | 2026-May | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 无 KM 图 |
| Patient-reported health-related quality of life in previously untreated chronic lymphocytic leukaemia: Results from the randomised phase 3 FLAIR trial comparing ibrutinib-rituximab versus fludarabine-cyclophosphamide-rituximab.Br J Haematol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:FIGURE 1:非 KM 图;FIGURE 2:生活质量量表图;FIGURE 3:生活质量量表图;FIGURE 4:生活质量量表图;FIGURE 5:生活质量量表图。 | PMID 41912408PMC13176521 | 2026-May | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Pitavastatin effects on lipids in relation to major adverse cardiovascular events: a REPRIEVE secondary analysis.Lancet HIV疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Figure 1::森林图/亚组分析图;Figure 2::森林图/亚组分析图;Figure 3::CONSORT/入组流程图。 | PMID 41936375PMC13122762 | 2026-May | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Baseline Alkaline Phosphatase Impacts Response Rates in Primary Biliary Cholangitis: Exploring Response to Elafibranor in ELATIVE.Liver Int疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:FIGURE 1:森林图/亚组分析图;FIGURE 2:森林图/亚组分析图;FIGURE 3:非 KM 图;FIGURE 4:森林图/亚组分析图;FIGURE 5:AI 判定为 other。 | PMID 41937506PMC13051278 | 2026-May | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial.Nat Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 6 张 PMC Figure,均未识别为 KM 图:Fig. 1:ROC 图;Fig. 2:森林图/亚组分析图;Fig. 3:森林图/亚组分析图;Extended Data Fig. 1:森林图/亚组分析图;Extended Data Fig. 2:森林图/亚组分析图;另有 1 张未列出。 | PMID 41942646PMC13190300 | 2026-May | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Efficacy, immunogenicity, and safety of a cell culture-derived quadrivalent influenza vaccine compared with a non-influenza vaccine in infants and children across five influenza seasons: a phase 3, multinational, observer-blind, randomised controlled trial.Lancet Child Adolesc Health疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41962984无 PMCID | 2026-May | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Pain and health-related quality-of-life outcomes with darolutamide in metastatic hormone-sensitive prostate cancer (ARANOTE): secondary and exploratory analyses of a multicentre, randomised, placebo-controlled, phase 3 trial.Lancet Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41969015无 PMCID | 2026-May | 0.95 | Eligible: Original result report of a Phase III randomized drug-intervention trial with time-to-event efficacy endpoints. While this specific abstract focuses on secondary/HRQoL outcomes, it reports formal results from the randomized trial including HRs for time-to-event endpoints. The primary trial (rPFS) is also referenced. Meets all inclusion criteria. | 无 KM 图 |
| Comparing the efficacy and safety of biosimilar BAT2506 with reference golimumab in patients with active psoriatic arthritis: 24-week results of a phase 3, multicenter, double-blind, randomized, parallel-group study.Expert Opin Biol TherPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 42021476无 PMCID | 2026-May | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Glenzocimab Efficacy and Safety Added to Intravenous Thrombolysis With or Without Mechanical Thrombectomy in Patients With Acute Ischemic Stroke-ACTISAVE: A Prospective, Randomized, Double-Blind Study.Stroke疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 2 张 PMC Figure,均未识别为 KM 图:Figure 1.:CONSORT/入组流程图;Figure 2.:森林图/亚组分析图。 | PMID 42044230PMC13117549 | 2026-May | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis.NEJM EvidPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 42047557无 PMCID | 2026-May | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Clonal Dynamics of Hematopoiesis in Aplastic Anemia after Immunosuppression and Eltrombopag.NEJM Evid疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 42047558无 PMCID | 2026-May | 0.90 | The record describes a secondary analysis of clonal dynamics from a Phase 3 randomized trial, but does not report on a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR) as required for eligibility. | 无 KM 图 |
| On-treatment serum prostate-specific antigen and overall survival in prostate cancer (STAMPEDE platform protocol): a post-hoc analysis of data from five phase 3 trials.Lancet Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 42061373无 PMCID | 2026-May | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 无 KM 图 |
| The Efficacy and Toxicity of CNS Prophylaxis in Diffuse Large B-Cell Lymphoma (CLSG-CNS-01): A Randomized, Multicenter, Prospective Phase 3 Trial.Hematol Oncol | PMID 42062177PMC13132674 | 2026-May | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Final results of nilotinib versus nilotinib combined with pegylated interferon alfa-2a as first-line therapy in chronic phase chronic myeloid leukaemia in France (PETALs): an open-label, multicentre, randomised phase 3 trial.Lancet Haematol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 42069411无 PMCID | 2026-May | 0.85 | Study is a randomized Phase 3 trial of a drug-containing intervention in human oncology (CP-CML) with a primary result report. However, the primary efficacy endpoint was a molecular response rate (MR4.5), not a time-to-event endpoint like OS, PFS, DFS, EFS, RFS, TTP, or an analysis with Kaplan-Meier/HR. The deterministic review signal confirms no time-to-event endpoint was identified. | 无 KM 图 |
| Comparability of aflibercept biosimilar with reference aflibercept in diabetic macular edema: subgroup analysis of the pivotal Phase-III INSIGHT randomized clinical trial.Expert Opin Biol TherPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 42104207无 PMCID | 2026-May | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Effect of Mirikizumab on Clinical and Endoscopic Outcomes Based on Prior Advanced Therapy Failure in Patients With Moderately to Severely Active Ulcerative Colitis.United European Gastroenterol J疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:研究设计图;FIGURE 2:图注未提示 KM 曲线;FIGURE 3:图注未提示 KM 曲线;FIGURE 4:图注未提示 KM 曲线;FIGURE 5:图注未提示 KM 曲线。 | PMID 42104877PMC13156813 | 2026-May | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Detection of Homologous Recombination Repair Gene Mutations by Tumor Tissue and Circulating Tumor DNA Testing in Prostate Cancer in the Phase III PROpel Trial.JCO Precis Oncol已检查 5 张 PubMed Figure,均未识别为 KM 图:FIG 1.:AI 判定为 flow diagram;FIG 2.:AI 判定为 flow diagram;FIG 3.:ROC 图;FIG 4.:AI 判定为 other;FIG 5.:AI 判定为 other。 | PMID 42114035PMC13182812 | 2026-May | 0.90 | This record reports on biomarker detection methodology and concordance analyses from the PROpel Phase III trial, not the primary efficacy results (e.g., rPFS or OS). It is an ancillary, secondary analysis. | 无 KM 图 |
| Mammographic surveillance in breast cancer patients aged 50 years or older: a synopsis of the Mammo-50 RCT.Health Technol Assess疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 42116552PMC13200029 | 2026-May | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 无 KM 图 |
| Acoramidis, Serum Transthyretin, and Cardiovascular Outcomes in Transthyretin Amyloid Cardiomyopathy: Insights From the ATTRibute-CM Trial.J Card FailPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 42128580无 PMCID | 2026-May | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Low-Dose Telmisartan/Amlodipine in Essential Hypertension: A Phase III Trial.J Clin Hypertens (Greenwich)疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:FIGURE 1:图注未提示 KM 曲线;FIGURE 2:图注未提示 KM 曲线;FIGURE 3:图注未提示 KM 曲线。 | PMID 42130156PMC13172608 | 2026-May | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Genomic analysis of Salmonella Typhi from a typhoid conjugate vaccine trial.Microb Genom疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:Fig. 1.:图注未提示 KM 曲线;Fig. 2.:图注未提示 KM 曲线;Fig. 3.:图注未提示 KM 曲线;Fig. 4.:图注未提示 KM 曲线。 | PMID 42149110PMC13183295 | 2026-May | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Evaluation of Sustained Disease Control With Nipocalimab Versus Placebo in the Phase 3 Vivacity-MG3 Study.Eur J NeurolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 42157574无 PMCID | 2026-May | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Concordance between clinician-reported toxicities and patient-reported symptom severity in early-stage breast cancer: an analysis of the randomized phase III PANTHER trial.ESMO Open疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 2 张 PMC Figure,均未识别为 KM 图:Figure 1:生活质量量表图;Figure 2:生活质量量表图。 | PMID 42215159PMC13242076 | 2026-May | 0.95 | The study is a secondary analysis of patient-reported outcomes and clinician-reported toxicities from a randomized phase III trial. While it is an oncology trial in humans with a drug intervention, the primary and key secondary endpoints are not time-to-event efficacy measures (e.g., OS, PFS, DFS). The analysis focuses on concordance between clinician- and patient-reported symptoms, not survival or progression endpoints. | 无 KM 图 |
| Regional Variations of Rates and Determinants of Drug Resistance Mutations in People Failing First-line Therapy for HIV-1: A Substudy from the D2EFT Phase 3b/4 Clinical Trial.Clin Infect Dis疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 8 张 PMC Figure,均未识别为 KM 图:Graphical Abstract:图注未提示 KM 曲线;Figure 1.:CONSORT/入组流程图;Figure 2.:图注未提示 KM 曲线;Figure 3.:CONSORT/入组流程图;Figure 4.:非 KM 图;另有 3 张未列出。 | PMID 41482685PMC13131943 | 2026-Apr-30 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Early Symptom Response in Patients With Uncomplicated Urinary Tract Infection Treated With Gepotidacin or Nitrofurantoin: Pooled Analysis From Two Pivotal Phase 3 Studies.Clin Infect Dis疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:Figure 1.:图注未提示 KM 曲线;Figure 2.:非 KM 图;Figure 3.:图注未提示 KM 曲线;Figure 4.:图注未提示 KM 曲线。 | PMID 41495938PMC13131927 | 2026-Apr-30 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Mim8 Bispecific Antibody Prophylaxis in Hemophilia A with or without Inhibitors.N Engl J MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 42054679无 PMCID | 2026-Apr-30 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| An indirect comparison of zanubrutinib vs acalabrutinib plus venetoclax in patients with treatment-naive CLL.Blood Adv入排复审未纳入:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | PMID 41587482PMC13094441 | 2026-Apr-28 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 无 KM 图 |
| CPX-351 selectively benefits patients with AML and myelodysplasia-related mutations in the pivotal randomized trial.Blood Adv | PMID 41628350PMC13133533 | 2026-Apr-28 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes: Results From the VESALIUS-CV Trial.JAMA疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41903215PMC13033171 | 2026-Apr-28 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Transdermal Estradiol Patches in Locally Advanced Prostate Cancer.N Engl J Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41880608无 PMCID | 2026-Apr-23 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Three Low-Dose Antihypertensive Agents in a Single Pill after Intracerebral Hemorrhage.N Engl J MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 42019018无 PMCID | 2026-Apr-23 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Oral Nirmatrelvir-Ritonavir for Covid-19 in Higher-Risk Outpatients.N Engl J Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 2 张 PMC Figure,均未识别为 KM 图:A:图注未提示 KM 曲线;B:图注未提示 KM 曲线。 | PMID 42019019PMC7619176 | 2026-Apr-23 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Chemoradiotherapy and transanal endoscopic surgery versus transanal endoscopic surgery alone in T1N0M0 rectal cancer: a multicenter, randomized, controlled, phase III clinical trial (TAUTEM-T1 study).Int J Colorectal DisAI 判定该论文不进入自动 KM 提取:This record describes the design and rationale of a trial, not the results of a completed Phase III RCT. | PMID 42026347PMC13236827 | 2026-Apr-23 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Single-cell dissection of persistent tumor antigens in non-responders reveals opportunities for TAA-targeted vaccination after neoadjuvant therapy in esophageal squamous cell carcinoma.J Immunother Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 7 张 PubMed Figure,均未识别为 KM 图:Figure 1:研究设计图;Figure 2:图注未提示 KM 曲线;Figure 3:图注未提示 KM 曲线;Figure 4:图注未提示 KM 曲线;Figure 5:图注未提示 KM 曲线;另有 2 张未列出。 | PMID 42019971PMC13110702 | 2026-Apr-22 | 0.45 | The record describes an original, human, randomized, Phase III, drug-intervention oncology trial. However, it does not report a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, HR, Kaplan-Meier). The study's primary endpoint appears to be pathological response and immune/tumor microenvironment analysis, not survival or progression. Therefore, eligibility cannot be confirmed based on the provided abstract. | 无 KM 图 |
| Tumor Debulking in Combination With Chemotherapy in Multiorgan Metastatic Colorectal Cancer: The ORCHESTRA Randomized Clinical Trial.JAMA疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41837962PMC12993731 | 2026-Apr-21 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Efficacy and Safety of Ultra-Low-Dose Immunotherapy in Relapsed Refractory Solid Tumors: Phase III Superiority Randomized Trial (DELII).J Clin Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41604598无 PMCID | 2026-Apr-20 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer.J Clin Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:FIG 1.:非 KM 图;FIG 2.:AI 判定为 multi panel km;FIG 3.:森林图/亚组分析图;FIG 4.:AI 判定为 multi panel km。 | PMID 41802242PMC13075786 | 2026-Apr-20 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 Study.J Clin Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41818638无 PMCID | 2026-Apr-20 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Relative efficacy, safety, and immunogenicity analysis of two doses versus one dose of recombinant coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomized, double blinded phase 3 trial.VaccinePubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41863180无 PMCID | 2026-Apr-19 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial.Lancet疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41974149无 PMCID | 2026-Apr-18 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study.Lancet疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41974150无 PMCID | 2026-Apr-18 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Ianalumab plus Eltrombopag in Immune Thrombocytopenia.N Engl J Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41363800无 PMCID | 2026-Apr-16 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Asundexian for Secondary Stroke Prevention.N Engl J MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41985132无 PMCID | 2026-Apr-16 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Randomized Trial of Adjunctive Prednisolone for Kawasaki Disease.N Engl J MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41985133无 PMCID | 2026-Apr-16 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| FDA Approval Summary: Durvalumab for the Treatment of Adult Patients with Muscle-Invasive Bladder Cancer.Clin Cancer Res | PMID 41678313PMC13127607 | 2026-Apr-15 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| STRATEGIC-1: multiple-line, randomized, open-label GERCOR-PRODIGE-39 phase III trial in unresectable RAS/BRAF wild-type metastatic colorectal cancer.Signal Transduct Target Ther | PMID 41980919PMC13079909 | 2026-Apr-14 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Deutenzalutamide, a novel androgen receptor inhibitor, after progression on docetaxel and abiraterone in metastatic castration-resistant prostate cancer: results from the randomized phase III HC-1119-04 trial.Signal Transduct Target Ther | PMID 41968137PMC13071078 | 2026-Apr-13 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 部分完成 |
| Adenovirus type 5 vector-based COVID-19 vaccine does not increase the likelihood of HIV infection.VaccinePubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41785679无 PMCID | 2026-Apr-11 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |